BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

INFLARX PHARMACEUTICALS, INC. — Lobbying — Receipts Report

LD-2 disclosure · 2nd Quarter - Report

INFLARX PHARMACEUTICALS, INC.

via FAEGRE DRINKER BIDDLE & REATH LLP

2nd Quarter (Apr 1 - June 30) · 2024Posted Jul 22, 2024Filing document ↗LDA record ↗

Coverage · No income or expenses were reported on this filing.

Client

Name: INFLARX PHARMACEUTICALS, INC.
Description: Pharmaceutical company.
Location: Michigan · United States of America

Registrant

Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Description: Law firm
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Health Issues
NIH panel review of GOHIBIC.
LobbyistsDAVID RUSGAN ZOOK · mr TIMOTHY R. FRANSON md
TargetedSENATE · Natl Institutes of Health (NIH)

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.